Overview
| Alternate Names: | Cancer of Prostate; Cancer of the Prostate; Cancer, Prostate; Cancer, Prostatic; Cancers, Prostate; Cancers, Prostatic; NGP - New growth of prostate; Neoplasm of prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate; Neoplasms, Prostatic; Prostate Cancer; Prostate Cancers; Prostate Neoplasm; Prostate Neoplasms; Prostatic Cancer; Prostatic Cancers; Prostatic Neoplasm; Tumour of prostate |
|---|---|
| PharmGKB Accession Id: | PA445425 |
| External Vocabularies |
|
In-Depth Annotations (
)
-
rs11568820
at chr12:46588812
in
VDR
In promoter; reduces the transcriptional activity; may be associated with prostate cancer risk.- Variant Name:
- VDR:Cdx2
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
http://www.pharmgkb.org/.../variant.jsp
Curated Annotations (
)
-
rs4646487
at chr1:47051762
in
CYP4B1
Risk or phenotype-associated allele: T Phenotype: The CYP4B1:rs4646487 T variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s):p = 0.008 Type of association: CO; TOX- Variant Name:
- CYP4B1:rs4646487 C>T; NM_000779.3:c.517C>T; NP_000770.2:p.Arg173Trp
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs1056836
at chr2:38151707
in
CYP1B1
A study in 264 unrelated primary open-angle glaucoma patients and 95 controls reportes that this variant in the CYP1B1 gene showed a statistically significant higher representation among primary open-angle glaucoma patients compared to controls. A study comparing the CYP1B1 genotypes in 164 Caucasian and 59 African-American breast cancer cases found that Caucasian patients with the Val/Val genotype have a significantly higher percentage of estrogen receptor-positive and progesterone receptor-positive breast cancers. Another study suggests that this SNP might play an important role in human prostate carcinogenesis. Other studies controversial discuss the association of CYP1B1 variants with cancer risk.This variant is also part of the defining SNPs for the CYP1B1*5, *6 and *7 allele.- Variant Name:
- CYP1B1: L432V; CYP1B1*3
- Related Diseases:
- Breast Neoplasms, Glaucoma, Prostatic Neoplasms
- Evidence:
-
PMID:11221602
PMID:15958554
PMID:16847423
PMID:18483560
PMID:9823305
-
rs1056836
at chr2:38151707
in
CYP1B1
In clincal studies of prostate cancer patients treated with docetaxel, CYP1B1*3 was associated with patient survival- Variant Name:
- CYP1B1*3;CYP1B1:4326 C>G; CYP1B1:L432V
- Related Drugs:
- docetaxel
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18187806
-
rs721048
at chr2:62985235
in
EHBP1
This SNP on 2p15 was shown to be associated with prostate cancer in a genome-wide SNP association study on over 23,000 Icelanders, followed by a replication study including over 15,500 individuals from Europe and the United States.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264098
-
rs1402467
at chr2:108361240
in
SULT1C4
Risk or phenotype-associated allele: G Phenotype: The SULT1C2: rs1402467 G variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0083 Type of association: PD; CO- Variant Name:
- SULT1C2:rs1402467 C>G; NM_006588.2:c.15C>G; NP_006579.2:p.Asp5Glu
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs6922548
at chr6:35461501
in
PPARD
Risk or phenotype-associated allele: G Phenotype: The PPAR delta SNP rs6922548 A>G was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0011 Type of association: PD; CO- Variant Name:
- PPARD:rs6922548 A>G;
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs7769719
at chr6:35470503
in
PPARD
Risk or phenotype-associated allele: G Phenotype: The PPAR delta SNP rs7769719 A>G was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0055 Type of association: PD; CO- Variant Name:
- PPARD:rs7769719 A>G
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs1883322
at chr6:35477784
in
PPARD
Risk or phenotype-associated allele: G Phenotype: The PPAR delta SNP rs1883322 A>G was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0061 Type of association: PD; CO- Variant Name:
- PPARD:rs1883322 A>G
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs2016520
at chr6:35486756
in
PPARD
Risk or phenotype-associated allele: G Phenotype: The PPAR delta SNP rs2016520 A>G was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0056 Type of association: PD; CO- Variant Name:
- PPARD:rs2016520 A>G; NM_006238.3:c.-87C>T
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs3734254
at chr6:35502988
in
PPARD
Risk or phenotype-associated allele: T Phenotype: The PPAR delta SNP rs3734254 C>T was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0089 Type of association: PD; CO- Variant Name:
- PPARD:rs3734254 C>T
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs680055
at chr7:99295541
in
CYP3A,
CYP3A43
The CYP3A43*3 allele is characterized by the P340A variant in exon 10. A study at 622 inicident prostate cancer cases and 396 controls suggests a role for this variant in prostate cancer etiology. Another study in African Americans and Caucasians suggests also that this SNP contibutes to prostate cancer risk.- Variant Name:
- CYP3A43: 1121C>G; *3; P340A
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:14695544
PMID:15548719
PMID:15894682
-
rs680055
at chr7:99295541
in
CYP3A,
CYP3A43
A study in 1,090 Caucasian prostate cancer cases found significant associations involved CYP3A43 P340A genotypes and history of benign prostatic hyperplasia (BPH). These results of the study suggest that androgen metabolism may act in concert with inflammatory phenotypes such as BPH in determining prostate cancer severity.- Variant Name:
- CYP3A43: P340A
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18566991
-
rs1799931
at chr8:18302650
in
NAT2
Risk or phenotype-associated allele: G Phenotype: The NAT2:rs1799931 G variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.003 Type of association: CO; TOX- Variant Name:
- NAT2:rs1799931 A>G; NM_000015.2:c.857G>A; NP_000006.2:p.Gly286Glu
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs4148943
at chr10:73439513
in
CHST3
Risk or phenotype-associated allele: C Phenotype: The CHST3:rs4148943 C variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0001 Type of association: PD; CO- Variant Name:
- CHST3:rs4148943 C>T; NM_004273.3:c.*1278C>T
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs4148945
at chr10:73439596
in
CHST3
Risk or phenotype-associated allele: C Phenotype: The CHST3:rs4148945 C variant was associated with positive clincial response (partial or complete response) to treatment and toxicity to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.011 (response); p = 0.010 (TOX) Type of association: PD; CO; TOX- Variant Name:
- CHST3:rs4148945 C>T; NM_004273.3:c.*1361C>T
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs4148947
at chr10:73440123
in
CHST3
Risk or phenotype-associated allele: C Phenotype: The CHST3:rs4148947 C variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0023 Type of association: PD; CO- Variant Name:
- CHST3:rs4148947 C>T; NM_004273.3:c.*1888T>C
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs4148950
at chr10:73441712
in
CHST3
Risk or phenotype-associated allele: A Phenotype: The CHST3:rs4148950 A variant was associated with positive clincial response (partial or complete response) to treatment and toxicity to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s):p = 0.024 (response); p = 0.006 (TOX) Type of association: PD; CO; TOX- Variant Name:
- CHST3:rs4148950 A>G; NM_004273.3:c.*3477G>A
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs1871450
at chr10:73442020
in
CHST3
Risk or phenotype-associated allele: A Phenotype: The CHST3:rs1871450 A variant was associated with positive clincial response (partial or complete response) to treatment and toxicity to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.048 (response); p = 0.006 (TOX) Type of association: PD; CO; TOX- Variant Name:
- CHST3:rs1871450 A>G; NM_004273.3:c.*3785G>A
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs730720
at chr10:73442768
in
CHST3
Risk or phenotype-associated allele: A Phenotype: The CHST3:rs730720 A variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0034 Type of association: PD; CO- Variant Name:
- CHST3:rs730720 A>G; NM_004273.3:c.*4533C>T
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs12418
at chr10:73443020
in
CHST3
Risk or phenotype-associated allele: A Phenotype: The CHST3:rs12418 A variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0005 Type of association: PD; CO- Variant Name:
- CHST3:rs12418 A>G; NM_004273.3:c.*4785G>A
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs2301159
at chr13:102495729
in
SLC10A2
Risk or phenotype-associated allele: T Phenotype: The SLC10A2:rs2301159 T variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.01 Type of association: CO; TOX- Variant Name:
- SLC10A2:rs2301159 C>T; NM_000452.2:c.*755C>T
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs2238472
at chr16:16159100
in
ABCC6
Risk or phenotype-associated allele: G Phenotype: The ABCC6 rs2238472 G variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.006 Type of association: CO; TOX- Variant Name:
- ABCC6:rs2238472 A>G; NM_001171.5:c.3803G>A; NP_001162.4:p.Arg1268Gln
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs2292954
at chr16:88140624
in
SPG7
Risk or phenotype-associated allele: T Phenotype: The SPG7:rs2292954 T variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0004 Type of association: CO; TOX- Variant Name:
- SPG7:rs2292954 C>T; NM_003119.2:c.1507A>G; NP_003110.1:p.Thr503Ala
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs12960
at chr16:88147829
in
RPL13,
SNORD68,
SPG7
Risk or phenotype-associated allele: G Phenotype: The SPG7:rs12960 G variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.004 Type of association: CO; TOX- Variant Name:
- SPG7:rs12960 A>G; NM_003119.2:c.2063G>A; NP_003110.1:p.Arg688Gln
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
-
rs11649743
at chr17:33149092
in
HNF1B
In a fine-mapping study in the HNF1B gene at 17q12 this variant was associated with prostate cancer risk.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18758462
-
rs4430796
at chr17:33172153
in
HNF1B
In a fine-mapping study in the HNF1B gene at 17q12 this variant was associated with prostate cancer risk.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18758462
-
rs4430796
at chr17:33172153
in
HNF1B
The A allele of rs4430796 contributes to the risk of prostate cancer in four populations of European descent and has a protective affect against Type 2 Diabetes.- Related Diseases:
- Diabetes Mellitus, Type 2, Prostatic Neoplasms
- Evidence:
-
PMID:17603485
-
rs1859962
at chr17:66620348
The G allele of rs1859962 was found to contribute to the risk of prostate cancer in four populations of European descent.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17603485
-
rs5945572
at chrX:51246423
This SNP on Xp11.22 was shown to be associated with prostate cancer in a genome-wide SNP association study on over 23,000 Icelanders, followed by a replication study including over 15,500 individuals from Europe and the United States.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264098
-
rs2227291
at chrX:77155158
in
ATP7A
Risk or phenotype-associated allele: G Phenotype: The ATP7A:rs2227291 G variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.006 Type of association: CO; TOX- Variant Name:
- ATP7A:rs2227291 C>G; NM_000052.4:c.2299G>C; NP_000043.3:p.Val767Leu
- Related Drugs:
- docetaxel, thalidomide
- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:20038957
Non-Curated Annotations (
)
-
rs721048
at chr2:62985235
in
EHBP1
GWAS Results: Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (Initial Sample Size: 1,854 cases, 21,372 controls; Replication Sample Size: 8,239 cases, 7,590 controls; Risk Allele: rs721048-A).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264098
http://www.genome.gov/gwastudies/
-
rs9311171
at chr3:37971481
in
CTDSPL
GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Prostate cancer.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17903305
http://www.genome.gov/gwastudies/
-
rs345013
at chr3:146656478
GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Prostate cancer.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17903305
http://www.genome.gov/gwastudies/
-
rs4466137
at chr5:83021495
in
HAPLN1
GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Prostate cancer.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17903305
http://www.genome.gov/gwastudies/
-
rs10498792
at chr6:51774590
in
PKHD1
GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Prostate cancer.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17903305
http://www.genome.gov/gwastudies/
-
rs9364554
at chr6:160753654
in
SLC22A3
GWAS Results: Multiple newly identified loci associated with prostate cancer susceptibility (Initial Sample Size: 1,854 cases, 1,894 controls; Replication Sample Size: 3,268 cases, 3,366 controls; Risk Allele: rs9364554-T).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264097
http://www.genome.gov/gwastudies/
-
rs10486567
at chr7:27943088
in
JAZF1
GWAS Results: Multiple loci identified in a genome-wide association study of prostate cancer (Initial Sample Size: 1,172 cases, 1,157 controls; Replication Sample Size: 3,941 cases, 3,964 controls; Risk Allele: rs10486567-G).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264096
http://www.genome.gov/gwastudies/
-
rs6465657
at chr7:97654263
in
LMTK2
GWAS Results: Multiple newly identified loci associated with prostate cancer susceptibility (Initial Sample Size: 1,854 cases, 1,894 controls; Replication Sample Size: 3,268 cases, 3,366 controls; Risk Allele: rs6465657-C).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264097
http://www.genome.gov/gwastudies/
-
rs16901979
at chr8:128194098
in
SRRM1L
GWAS Results: Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 (Initial Sample Size: 1,435 cases, 3,064 controls; Replication Sample Size: 1,210 EA cases, 2,445 EA controls; 373 AA cases, 372 AA controls; Risk Allele: rs16901979-A).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17401366
http://www.genome.gov/gwastudies/
-
rs6983267
at chr8:128482487
GWAS Results: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 (Initial Sample Size: 1,172 cases, 1,157 controls; Replication Sample Size: 3,124 cases, 3,142 controls; Risk Allele: rs6983267-G).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17401363
http://www.genome.gov/gwastudies/
-
rs10993994
at chr10:51219502
in
MSMB
GWAS Results: Multiple loci identified in a genome-wide association study of prostate cancer (Initial Sample Size: 1,172 cases, 1,157 controls; Replication Sample Size: 3,941 cases, 3,964 controls; Risk Allele: rs10993994-T).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264096
http://www.genome.gov/gwastudies/
-
rs10993994
at chr10:51219502
in
MSMB
GWAS Results: Multiple newly identified loci associated with prostate cancer susceptibility (Initial Sample Size: 1,854 cases, 1,894 controls; Replication Sample Size: 3,268 cases, 3,366 controls; Risk Allele: rs10993994-T).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264097
http://www.genome.gov/gwastudies/
-
rs4962416
at chr10:126686862
in
CTBP2
GWAS Results: Multiple loci identified in a genome-wide association study of prostate cancer (Initial Sample Size: 1,172 cases, 1,157 controls; Replication Sample Size: 3,941 cases, 3,964 controls; Risk Allele: rs4962416-C).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264096
http://www.genome.gov/gwastudies/
-
rs7931342
at chr11:68751073
GWAS Results: Multiple newly identified loci associated with prostate cancer susceptibility (Initial Sample Size: 1,854 cases, 1,894 controls; Replication Sample Size: 3,268 cases, 3,366 controls; Risk Allele: rs7931342-G).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264097
http://www.genome.gov/gwastudies/
-
rs10896449
at chr11:68751243
GWAS Results: Multiple loci identified in a genome-wide association study of prostate cancer (Initial Sample Size: 1,172 cases, 1,157 controls; Replication Sample Size: 3,941 cases, 3,964 controls; Risk Allele: rs10896449-G).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264096
http://www.genome.gov/gwastudies/
-
rs1529276
at chr13:102726008
GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Prostate cancer.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17903305
http://www.genome.gov/gwastudies/
-
rs4430796
at chr17:33172153
in
HNF1B
GWAS Results: Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes (Initial Sample Size: 1,501 cases, 11,290 controls; Replication Sample Size: 1,992 cases, 3,058 controls; Risk Allele: rs4430796-A).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17603485
http://www.genome.gov/gwastudies/
-
rs1859962
at chr17:66620348
GWAS Results: Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes (Initial Sample Size: 1,501 cases, 11,290 controls; Replication Sample Size: 1,992 cases, 3,058 controls; Risk Allele: rs1859962-G).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:17603485
http://www.genome.gov/gwastudies/
-
rs2735839
at chr19:56056435
in
KLK3
GWAS Results: Multiple newly identified loci associated with prostate cancer susceptibility (Initial Sample Size: 1,854 cases, 1,894 controls; Replication Sample Size: 3,268 cases, 3,366 controls; Risk Allele: rs2735839-G).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264097
http://www.genome.gov/gwastudies/
-
rs9623117
at chr22:38782065
in
TNRC6B
GWAS results: Sequence variants at 22q13 are associated with prostate cancer risk. (Initial Sample Size: 1,235 aggressive cases, 1,599 controls; Replication Sample Size: 3,629 aggressive cases, 4,255 non-aggressive cases, 5,738 controls); (Region: 22q13.1; Reported Gene(s): TNRC6B; Risk Allele: rs9623117-C); (p-value= 0.0000005).This variant is associated with Prostate cancer.- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:19117981
http://www.genome.gov/gwastudies/
-
rs5945572
at chrX:51246423
GWAS Results: Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (Initial Sample Size: 1,854 cases, 21,372 controls; Replication Sample Size: 8,239 cases, 7,590 controls; Risk Allele: rs5945572-A).- Related Diseases:
- Prostatic Neoplasms
- Evidence:
-
PMID:18264098
http://www.genome.gov/gwastudies/
Variant names are different names that have been used in the literature and other resources to
refer to the same variant.
Non-curated variant information is accumulated solely by computational methods and has not
been verified by the scientific staff at PharmGKB.
Curated Information
The following genes are in curated knowledge about this disease.
Non-Curated Information
A list of non-curated publications that mention this disease along with other genes is available.
Curated Information
The following drugs are in curated knowledge about this disease.
| Drug Class | Relationship | Evidence | |
|---|---|---|---|
|
Antiandrogens |
|
Publications |
| Drug | Relationship | Evidence | |
|---|---|---|---|
|
|
2-methoxyestradiol |
|
Publications |
|
|
celecoxib |
|
Publications |
|
docetaxel |
|
Publications, Variants |
|
|
estramustine |
|
Publications |
|
|
irinotecan |
|
Publications |
|
|
sorafenib |
|
Publications |
|
|
staurosporine |
|
Publications |
|
|
testosterone |
|
Publications |
|
|
thalidomide |
|
Publications, Variants |
|
|
vinorelbine |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this disease along with other drugs is available.
Non-Curated Information
A list of non-curated publications that mention this disease along with other diseases is available.
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
Common Searches
Search Medline Plus
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this disease is available.